Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Laura Q.M. Chow"'
Autor:
Terrill McClanahan, Joanne E. Tomassini, Masahisa Handa, Tanguy Y. Seiwert, Laura Q.M. Chow, Jonathan Cheng, Jared Lunceford, Jonathan Juco, Erin Murphy, Christina Moon, Ni Yu, Christopher Gibson, Jennifer H. Yearley
Supplementary Figures S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64361e96b795e8de0c66995d095d08cd
https://doi.org/10.1158/1078-0432.22462622
https://doi.org/10.1158/1078-0432.22462622
Autor:
Renato Martins, Keith Eaton, Laura Q.M. Chow, Christina S. Baik, Bernardo Goulart, Rafael Santana-Davila, Sylvia M. Lee, Venu G. Pillarisetty, Xiuyun Jiang, Jonathan R. Fromm, Jenna Voutsinas, Qian (Vicky) Wu, Cristina P. Rodriguez
Purpose:This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC).Patients and Methods:Patients with progressing incurable HN and SGC, Eastern
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2aacf0ad3600b9a6de56ff357102155
https://doi.org/10.1158/1078-0432.c.6529320.v1
https://doi.org/10.1158/1078-0432.c.6529320.v1
Autor:
Renato Martins, Keith Eaton, Laura Q.M. Chow, Christina S. Baik, Bernardo Goulart, Rafael Santana-Davila, Sylvia M. Lee, Venu G. Pillarisetty, Xiuyun Jiang, Jonathan R. Fromm, Jenna Voutsinas, Qian (Vicky) Wu, Cristina P. Rodriguez
Supplement Figure 1: Synergistic cytotoxic effect of pembrolizumab combined with vorinostat in HNSCC tissue slice culture. HNSCC slices (250 ï�m) were cultured and treated with 20 ï�g/ml of isotype control antibody IgG4 or pembrolizumab, wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3652603a9653a9a1238a7a9690a998c0
https://doi.org/10.1158/1078-0432.22476186.v1
https://doi.org/10.1158/1078-0432.22476186.v1
Autor:
Dong-Wan Kim, Michael Shi, Fabrice Branle, Yuanbo Song, Pilar Cazorla Arratia, Felipe K. Hurtado, Pilar Garrido, Chong-Jen Yu, Mark McKeage, Margarita Majem, Rita Chiari, Sergey Orlov, Chao-Hua Chiu, Patrick Y. Wen, Heather A. Wakelee, Martin J. van den Bent, Erin M. Bertino, Fabrice Barlesi, Laura Q.M. Chow
Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24226e2956b609fbeacadf7acd378005
https://doi.org/10.1158/1078-0432.22482206
https://doi.org/10.1158/1078-0432.22482206
Autor:
Laura Q.M. Chow, Neal D. Futran, Renato Martins, Rafael Santana-Davila, Ganesh M. Mugundu, Eric Q. Konnick, R. Alex Harbison, Ahmed Diab, Sharat Raju, Michael C. Kao, Cristina P. Rodriguez, Eduardo Méndez
supplemental tables and legends (no revisions, re-uploaded)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208eb5a47144714ff56beac04dfd059f
https://doi.org/10.1158/1078-0432.22470447.v1
https://doi.org/10.1158/1078-0432.22470447.v1
Autor:
Dong-Wan Kim, Michael Shi, Fabrice Branle, Yuanbo Song, Pilar Cazorla Arratia, Felipe K. Hurtado, Pilar Garrido, Chong-Jen Yu, Mark McKeage, Margarita Majem, Rita Chiari, Sergey Orlov, Chao-Hua Chiu, Patrick Y. Wen, Heather A. Wakelee, Martin J. van den Bent, Erin M. Bertino, Fabrice Barlesi, Laura Q.M. Chow
Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0074b4f26586ca29ac01ce7327652a3e
https://doi.org/10.1158/1078-0432.22482203
https://doi.org/10.1158/1078-0432.22482203
Autor:
Laura Q.M. Chow, Emmett V. Schmidt, Nuzhat Pathan, Aron D. Thall, Ying Chen, Dhiraj Gambhire, Bo Huang, Donna Di Gravio, Drew W. Rasco, Amita Patnaik, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Mario Sznol, Anthony W. Tolcher
Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137 in combination with the humaniz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6766cae734be63dd75a5936338ec69d8
https://doi.org/10.1158/1078-0432.c.6526895
https://doi.org/10.1158/1078-0432.c.6526895
Autor:
Laura Q.M. Chow, Emmett V. Schmidt, Nuzhat Pathan, Aron D. Thall, Ying Chen, Dhiraj Gambhire, Bo Huang, Donna Di Gravio, Drew W. Rasco, Amita Patnaik, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Mario Sznol, Anthony W. Tolcher
Table S1. Patient flow by dose group Table S2. PK parameters of utomilumab following multiple dosing Figure S1. Partial response in a patient with anaplastic thyroid carcinoma (utomilumab 3.6 mg/kg + pembrolizumab 2 mg/kg) at cycle 4 versus baseline.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d00ed2207eedc70c665158d99df5b8
https://doi.org/10.1158/1078-0432.22468295.v1
https://doi.org/10.1158/1078-0432.22468295.v1
Autor:
Laura Q.M. Chow, Neal D. Futran, Renato Martins, Rafael Santana-Davila, Ganesh M. Mugundu, Eric Q. Konnick, R. Alex Harbison, Ahmed Diab, Sharat Raju, Michael C. Kao, Cristina P. Rodriguez, Eduardo Méndez
Correlative translational pharmacodynamics data revised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d485f85e5dfae94124add4abdf9c632
https://doi.org/10.1158/1078-0432.22470441.v1
https://doi.org/10.1158/1078-0432.22470441.v1
Autor:
Laura Q.M. Chow, Erick Gamelin, Robert Janssen, Mary J. Janatpour, Robert L. Coffman, Albert Candia, Amy L. Cummings, Joseph Leach, Lyudmila Bazhenova, Melissa Johnson, Alexander I. Spira, Edward B. Garon
Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::487d7d4f227be75a79f5363a442f9217
https://doi.org/10.1158/1078-0432.22480679.v1
https://doi.org/10.1158/1078-0432.22480679.v1